Scrip is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Desitin Pharmaceuticals GmbH

http://www.desitinpharma.com/

Latest From Desitin Pharmaceuticals GmbH

GSK sells off US rights to migraine drug

GlaxoSmithKline has sold its US rights to migraine drug Treximet (sumatriptan/naproxen) to Pernix Therapeutics for $250m. GSK licensed the rights from Pozen under a collaboration that began in 2003. US sales in 2013 were $79m, so the deal almost doubles Pernix's revenues.

Neurology Canada

Deals Shaping The Medical Industry, June 2012

The Dealmaking column is a survey of recent transactions, including strategic alliances, mergers & acquisitions, and financings, in the life sciences industries. Deals are listed by the following industry sectors: in vitro diagnostics, medical devices, pharmaceuticals, and research/analytical instrumentation and reagents. All transactions are excerpted from Elsevier's Strategic Transactions database, providing comprehensive transaction coverage from 1991 to the present.

BioPharmaceutical Medical Device

Migraine Snapshot: Despite Significant Generic Presence, MAP, Allergan, Others See Big Market Potential

After a 20-year hiatus, the market for acute and chronic migraine is set to expand with the introduction of Allergan’s Botox and of novel formulations of triptans and alternative therapies.

BioPharmaceutical North America

Deals Of The Week: GSK/HGSI, Daiichi Sankyo/Coherus

GSK/Human Genome story takes a sharp turn, but does the big pharma’s hostile bid expose greater interest in cardiovascular drug darapladib than it is admitting?

BioPharmaceutical Business Strategies
See All

Company Information

  • Industry
  • Pharmaceuticals
  • Other Names / Subsidiaries
    • Desitin Arzneimittel GmbH
UsernamePublicRestriction

Register